RU2015125349A - МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА ПРОТИВ АКТИВИРОВАННОГО БЕЛКА С (аРС) - Google Patents
МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА ПРОТИВ АКТИВИРОВАННОГО БЕЛКА С (аРС) Download PDFInfo
- Publication number
- RU2015125349A RU2015125349A RU2015125349A RU2015125349A RU2015125349A RU 2015125349 A RU2015125349 A RU 2015125349A RU 2015125349 A RU2015125349 A RU 2015125349A RU 2015125349 A RU2015125349 A RU 2015125349A RU 2015125349 A RU2015125349 A RU 2015125349A
- Authority
- RU
- Russia
- Prior art keywords
- amino acid
- seq
- acid sequence
- variable region
- nos
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 67
- 101800004937 Protein C Proteins 0.000 claims 26
- 102000017975 Protein C Human genes 0.000 claims 26
- 101800001700 Saposin-D Proteins 0.000 claims 26
- 229960000856 protein c Drugs 0.000 claims 26
- 230000014508 negative regulation of coagulation Effects 0.000 claims 10
- 150000001413 amino acids Chemical class 0.000 claims 8
- 238000012986 modification Methods 0.000 claims 8
- 230000004048 modification Effects 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 206010053567 Coagulopathies Diseases 0.000 claims 4
- 208000015294 blood coagulation disease Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 claims 3
- 102000055691 human APC Human genes 0.000 claims 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims 2
- 102100022641 Coagulation factor IX Human genes 0.000 claims 2
- 102220543692 Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas_N53G_mutation Human genes 0.000 claims 2
- 208000032843 Hemorrhage Diseases 0.000 claims 2
- 208000034158 bleeding Diseases 0.000 claims 2
- 230000000740 bleeding effect Effects 0.000 claims 2
- 239000003114 blood coagulation factor Substances 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102220566102 Antileukoproteinase_L97G_mutation Human genes 0.000 claims 1
- 102220545207 Carbohydrate sulfotransferase 6_S98W_mutation Human genes 0.000 claims 1
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 1
- 102220498119 Electron transfer flavoprotein subunit beta_S96A_mutation Human genes 0.000 claims 1
- 102220574236 Ellis-van Creveld syndrome protein_N54A_mutation Human genes 0.000 claims 1
- 108010076282 Factor IX Proteins 0.000 claims 1
- 108010054218 Factor VIII Proteins 0.000 claims 1
- 102000001690 Factor VIII Human genes 0.000 claims 1
- 201000003542 Factor VIII deficiency Diseases 0.000 claims 1
- 108010054265 Factor VIIa Proteins 0.000 claims 1
- 208000009292 Hemophilia A Diseases 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102220465272 Interferon alpha-8_N53K_mutation Human genes 0.000 claims 1
- 102220618489 Isocitrate dehydrogenase [NAD] subunit gamma, mitochondrial_N54Q_mutation Human genes 0.000 claims 1
- 102220509487 Kinesin-like protein KIF2C_S95E_mutation Human genes 0.000 claims 1
- 102220471249 M-phase inducer phosphatase 1_S82A_mutation Human genes 0.000 claims 1
- 102220637940 Probable cation-transporting ATPase 13A5_S96Y_mutation Human genes 0.000 claims 1
- 102100023097 Protein S100-A1 Human genes 0.000 claims 1
- 102220639964 Radial spoke head protein 3 homolog_S56A_mutation Human genes 0.000 claims 1
- 102220483412 Tensin-2_G99E_mutation Human genes 0.000 claims 1
- 102220477940 Triggering receptor expressed on myeloid cells 1_T25S_mutation Human genes 0.000 claims 1
- 102100040418 Tumor protein D52 Human genes 0.000 claims 1
- 102220555263 Tumor protein D52_D52Y_mutation Human genes 0.000 claims 1
- 230000023555 blood coagulation Effects 0.000 claims 1
- 102220360203 c.162C>A Human genes 0.000 claims 1
- 102220358488 c.167G>A Human genes 0.000 claims 1
- 102220418059 c.283A>G Human genes 0.000 claims 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 1
- 230000015271 coagulation Effects 0.000 claims 1
- 238000005345 coagulation Methods 0.000 claims 1
- 208000011664 congenital factor XI deficiency Diseases 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000007219 factor XI deficiency Diseases 0.000 claims 1
- 229960004222 factor ix Drugs 0.000 claims 1
- 229940012414 factor viia Drugs 0.000 claims 1
- 229960000301 factor viii Drugs 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 208000009429 hemophilia B Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 102200090659 rs137852502 Human genes 0.000 claims 1
- 102200099928 rs137853185 Human genes 0.000 claims 1
- 102220285537 rs1381256979 Human genes 0.000 claims 1
- 102220088953 rs144098296 Human genes 0.000 claims 1
- 102220277874 rs146221748 Human genes 0.000 claims 1
- 102220112600 rs147886860 Human genes 0.000 claims 1
- 102220267892 rs1555193020 Human genes 0.000 claims 1
- 102200104290 rs1557052294 Human genes 0.000 claims 1
- 102220253369 rs201879717 Human genes 0.000 claims 1
- 102200066087 rs267607277 Human genes 0.000 claims 1
- 102200068694 rs281865207 Human genes 0.000 claims 1
- 102220005551 rs33960522 Human genes 0.000 claims 1
- 102200118227 rs34579351 Human genes 0.000 claims 1
- 102200118229 rs34665886 Human genes 0.000 claims 1
- 102220128896 rs376207606 Human genes 0.000 claims 1
- 102220034241 rs483352780 Human genes 0.000 claims 1
- 102220075323 rs540745201 Human genes 0.000 claims 1
- 102200074433 rs587783537 Human genes 0.000 claims 1
- 102220330013 rs78488639 Human genes 0.000 claims 1
- 102220093647 rs876661194 Human genes 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 239000004404 sodium propyl p-hydroxybenzoate Substances 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 102220588467 von Willebrand factor A domain-containing protein 5B1_S96R_mutation Human genes 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261731294P | 2012-11-29 | 2012-11-29 | |
| US61/731,294 | 2012-11-29 | ||
| US201361786472P | 2013-03-15 | 2013-03-15 | |
| US61/786,472 | 2013-03-15 | ||
| PCT/US2013/072243 WO2014085596A1 (en) | 2012-11-29 | 2013-11-27 | MONOCLONAL ANTIBODIES AGAISNT ACTIVATED PROTEIN C (aPC) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015125349A true RU2015125349A (ru) | 2017-01-10 |
Family
ID=50828462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015125349A RU2015125349A (ru) | 2012-11-29 | 2013-11-27 | МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА ПРОТИВ АКТИВИРОВАННОГО БЕЛКА С (аРС) |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20150307625A1 (enExample) |
| EP (1) | EP2925351A4 (enExample) |
| JP (1) | JP2016501230A (enExample) |
| KR (1) | KR20150088869A (enExample) |
| CN (1) | CN104812402A (enExample) |
| AR (1) | AR093671A1 (enExample) |
| AU (1) | AU2013352159A1 (enExample) |
| BR (1) | BR112015012414A2 (enExample) |
| CA (1) | CA2892750A1 (enExample) |
| HK (1) | HK1212896A1 (enExample) |
| IL (1) | IL238658A0 (enExample) |
| MX (1) | MX2015006424A (enExample) |
| RU (1) | RU2015125349A (enExample) |
| SG (1) | SG11201503719WA (enExample) |
| TW (1) | TW201429992A (enExample) |
| UY (1) | UY35154A (enExample) |
| WO (1) | WO2014085596A1 (enExample) |
| ZA (1) | ZA201504659B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017087391A1 (en) * | 2015-11-17 | 2017-05-26 | Bayer Healthcare, Llc | Epitope of optimized humanized monoclonal antibodies against activated protein c and uses thereof |
| EP3831843A1 (en) * | 2019-12-08 | 2021-06-09 | Royal College Of Surgeons In Ireland | A hemostatic agent and uses thereof |
| CN115611986B (zh) * | 2021-07-13 | 2025-08-12 | 上海莱士血液制品股份有限公司 | 针对人活化蛋白c的单克隆抗体及其制备和应用 |
| CN116496394B (zh) * | 2022-01-26 | 2024-07-23 | 东莞市朋志生物科技有限公司 | 抗s100蛋白的抗体、检测s100蛋白的试剂和试剂盒 |
| US20250163183A1 (en) * | 2022-03-04 | 2025-05-22 | Coagulant Therapeutics Corporation | Camelid antibodies against activated protein c and uses thereof |
| CN118370814A (zh) * | 2023-01-20 | 2024-07-23 | 上海莱士血液制品股份有限公司 | 一种抗aPC单克隆抗体的制剂及其应用 |
| AU2024252640A1 (en) | 2023-04-07 | 2025-10-02 | Diagonal Therapeutics Inc. | Bispecific agonistic antibodies to activin a receptor like type 1 (alk1) |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993009804A1 (en) * | 1991-11-18 | 1993-05-27 | The Scripps Research Institute | Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation |
| DE69735421T2 (de) * | 1996-04-24 | 2006-10-19 | The Regents Of The University Of Michigan, Ann Arbor | Gegen inaktivierung resistenter faktor viii |
| US6989241B2 (en) * | 2000-10-02 | 2006-01-24 | Oklahoma Medical Research Foundation | Assay for rapid detection of human activated protein C and highly specific monoclonal antibody therefor |
| US20030226155A1 (en) * | 2001-08-30 | 2003-12-04 | Biorexis Pharmaceutical Corporation | Modified transferrin-antibody fusion proteins |
| US20030203355A1 (en) * | 2002-04-24 | 2003-10-30 | Los Alamos National Laboratory | Fluorobodies: binding ligands with intrinsic fluorescence |
| GB0309126D0 (en) * | 2003-04-17 | 2003-05-28 | Neutec Pharma Plc | Clostridium difficile focussed antibodies |
| WO2006017538A2 (en) * | 2004-08-03 | 2006-02-16 | Dyax Corp. | Hk1-binding proteins |
| AU2005318171B2 (en) * | 2004-12-20 | 2011-09-29 | Crucell Holland B.V. | Binding molecules capable of neutralizing West Nile virus and uses thereof |
| US7939637B2 (en) * | 2005-12-13 | 2011-05-10 | Medimmune Limited | Insulin-like growth factor antibodies and uses thereof |
| US8039597B2 (en) * | 2007-09-07 | 2011-10-18 | Agensys, Inc. | Antibodies and related molecules that bind to 24P4C12 proteins |
| TWI489993B (zh) * | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法 |
| WO2009055669A2 (en) * | 2007-10-26 | 2009-04-30 | Oklahoma Medical Research Foundation | Monoclonal antibodies against activated and unactivated protein c |
| GB0903151D0 (en) * | 2009-02-25 | 2009-04-08 | Bioinvent Int Ab | Antibody uses and methods |
| US8926976B2 (en) * | 2009-09-25 | 2015-01-06 | Xoma Technology Ltd. | Modulators |
| GB201011771D0 (en) * | 2010-07-13 | 2010-08-25 | Bioinvent Int Ab | Biological material and particular uses thereof |
| GB201013989D0 (en) * | 2010-08-20 | 2010-10-06 | Univ Southampton | Biological materials and methods of using the same |
| EP2640421A4 (en) * | 2010-11-16 | 2014-05-28 | Medimmune Llc | THERAPIES FOR TREATMENTS WITH ANTI-IGF ANTIBODIES |
| US8440797B2 (en) * | 2010-12-06 | 2013-05-14 | Dainippon Sumitomo Pharma Co., Ltd. | Human monoclonal antibody |
| GB201020995D0 (en) * | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
-
2013
- 2013-11-27 RU RU2015125349A patent/RU2015125349A/ru not_active Application Discontinuation
- 2013-11-27 HK HK16100878.9A patent/HK1212896A1/zh unknown
- 2013-11-27 MX MX2015006424A patent/MX2015006424A/es unknown
- 2013-11-27 WO PCT/US2013/072243 patent/WO2014085596A1/en not_active Ceased
- 2013-11-27 US US14/443,710 patent/US20150307625A1/en not_active Abandoned
- 2013-11-27 CN CN201380062159.XA patent/CN104812402A/zh active Pending
- 2013-11-27 AU AU2013352159A patent/AU2013352159A1/en not_active Abandoned
- 2013-11-27 SG SG11201503719WA patent/SG11201503719WA/en unknown
- 2013-11-27 CA CA2892750A patent/CA2892750A1/en not_active Abandoned
- 2013-11-27 EP EP13857869.5A patent/EP2925351A4/en not_active Withdrawn
- 2013-11-27 JP JP2015545438A patent/JP2016501230A/ja active Pending
- 2013-11-27 BR BR112015012414A patent/BR112015012414A2/pt not_active IP Right Cessation
- 2013-11-27 KR KR1020157017008A patent/KR20150088869A/ko not_active Withdrawn
- 2013-11-28 UY UY0001035154A patent/UY35154A/es not_active Application Discontinuation
- 2013-11-28 TW TW102143366A patent/TW201429992A/zh unknown
- 2013-11-29 AR ARP130104417A patent/AR093671A1/es unknown
-
2015
- 2015-05-06 IL IL238658A patent/IL238658A0/en unknown
- 2015-06-26 ZA ZA2015/04659A patent/ZA201504659B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013352159A1 (en) | 2015-06-04 |
| AR093671A1 (es) | 2015-06-17 |
| KR20150088869A (ko) | 2015-08-03 |
| CN104812402A (zh) | 2015-07-29 |
| ZA201504659B (en) | 2017-11-29 |
| EP2925351A1 (en) | 2015-10-07 |
| US20150307625A1 (en) | 2015-10-29 |
| BR112015012414A2 (pt) | 2017-09-12 |
| JP2016501230A (ja) | 2016-01-18 |
| HK1212896A1 (zh) | 2016-06-24 |
| UY35154A (es) | 2014-06-30 |
| IL238658A0 (en) | 2015-06-30 |
| TW201429992A (zh) | 2014-08-01 |
| EP2925351A4 (en) | 2016-08-24 |
| MX2015006424A (es) | 2015-08-14 |
| WO2014085596A1 (en) | 2014-06-05 |
| CA2892750A1 (en) | 2014-06-05 |
| SG11201503719WA (en) | 2015-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015125349A (ru) | МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА ПРОТИВ АКТИВИРОВАННОГО БЕЛКА С (аРС) | |
| JP2016501230A5 (enExample) | ||
| ES2535365T3 (es) | Tratamiento de trastornos relacionados con TNF alfa | |
| JP7759067B2 (ja) | 広域中和抗ｈｉｖ－１抗体およびその使用方法 | |
| RU2421464C2 (ru) | Человеческие антитела к il-13 и их терапевтическое применение | |
| ES2605945T3 (es) | Anticuerpos de unión a Tweak | |
| RU2016129113A (ru) | Антитела к pd-1 собак | |
| JP2020039360A5 (enExample) | ||
| IL301607B2 (en) | Compositions and methods for growth factor modulation | |
| RU2019121086A (ru) | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) | |
| RU2009149294A (ru) | Антиген-связывающие белки, нацеленные на orf0657n s.aureus | |
| JP2016188209A5 (enExample) | ||
| RU2011101969A (ru) | Антитела к человеческому интерлейкину-20 | |
| JP2020514277A5 (enExample) | ||
| RU2018125515A (ru) | Антитело против c5 и способ предупреждения и лечения обусловленных комплементом заболеваний | |
| HRP20220918T1 (hr) | Anti-transtiretinska antitijela | |
| JP2012519712A5 (enExample) | ||
| FI3978522T3 (fi) | Humaaneja vasta-aineita Fel d1:lle ja niiden käyttömenetelmiä | |
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| JP2018510617A5 (enExample) | ||
| KR20130043168A (ko) | 이원 가변 도메인 면역글로불린 및 이의 용도 | |
| JP2014525933A5 (enExample) | ||
| TW201313738A (zh) | 人類類血管生成素蛋白３之人類抗體 | |
| RS59955B1 (sr) | Anti-c5a vezujuće grupe sa visokom blokirajućom aktivnosti | |
| EP2970457A2 (en) | Dual specific binding proteins directed against tnf |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20161128 |